Trial Profile

A Single-arm, Open-label, Multi-center Phase 2 Study of Enfortumab Vedotin (ASG-22CE) in Chinese Subjects With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and PD 1/PD-L1 Inhibitor Therapy (EV-203)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 21 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enfortumab vedotin (Primary)
Indications Adenocarcinoma; Bladder cancer; Carcinoma; Pelvic cancer; Renal cancer; Squamous cell cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
Focus Pharmacokinetics; Therapeutic Use
Acronyms EV-203
Sponsors Astellas Pharma China

04 Oct 2024 Planned End Date changed from 30 Sep 2024 to 31 Oct 2025.
19 Aug 2024 According to an Astellas Pharma media release, Professor Guo Jun Iis the Principal Investigator of this EV-203 trial.
06 Nov 2023 Planned End Date changed from 31 Jan 2024 to 30 Sep 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com